Skip to main content
. 2017 Jul 28;9(1):56–65. doi: 10.1007/s13340-017-0330-2

Fig. 3.

Fig. 3

a ΔHbA1c level at 3 months after the start of therapy according to concomitant drug type (age ≥ 75 years). b ΔHbA1c level at 3 months after the start of therapy according to concomitant drug type (age 65–74 years). c ΔHbA1c level at 3 months after the start of therapy according to concomitant drug type (age < 65 years)